Eftilagimod Alfa is a fusion protein commercialized by Immutep, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 24 clinical trials, of which 12 were completed, 6 are ongoing, 3 are planned, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Eftilagimod Alfas valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Eftilagimod Alfa is expected to reach an annual total of $277 mn by 2038 globally based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Eftilagimod Alfa Overview
Eftilagimod alfa (IMP-321, EDP-202) is under development for the treatment of HER2-negative hormone receptor-positive metastatic breast cancer, soft tissue sarcoma including undifferentiated pleomorphic sarcoma (UPS), myxofibrosarcoma, dedifferentiated liposarcoma (DDLPS), myxoid and round cell liposarcoma (MRCLPS), epithelioid sarcoma (ES), angiosarcoma (AS), peritoneal cancer, non-squamous non-small cell lung cancer (NSCLC), recurrent head and neck cancer squamous cell carcinoma, as an adjuvant therapy for metastatic melanoma, hepatocellular carcinoma, metastatic urothelial cancer and solid tumors. It is administered through subcutaneous, intratumoral and intraperitoneal routes. It is a recombinant soluble human lymphocyte-activation gene 3 (LAG-3) IgG Fc fusion protein. The drug candidate is developed by using ImmuFact technology.
The drug candidate was also under development for triple-negative breast cancer, pancreatic adenocarcinoma, metastatic renal cell carcinoma, coronavirus disease 2019 and prostate cancer.
Immutep Overview
Immutep is a developer of immunotherapeutic products for the treatment of cancer and autoimmune diseases. The company provides products based on the LAG-3 immune control mechanism which is active in the regulation of the T cell immune response. It develops IMP761, a humanized monoclonal antibody that binds to LAG-3 and autoreactive T-cells as an agonist to reduce immune reactions in autoimmune diseases, and others. Immuteps IMP321 is in clinical development for the treatment of a range of cancer indications. The company partners with pharmaceutical and biotech companies for research and development activities. It has operations across Australia, Germany and France. Immutep is headquartered in Sydney, New South Wales, Australia.
The company reported revenues of (Australian Dollars) AUD0.2 million for the fiscal year ended June 2023 (FY2023), a decrease of 24.4% over FY2022. The operating loss of the company was AUD44.9 million in FY2023, compared to an operating loss of AUD34.2 million in FY2022. The net loss of the company was AUD39.9 million in FY2023, compared to a net loss of AUD32.2 million in FY2022.
For a complete picture of Eftilagimod Alfas valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.